Physician profile
Daniela Haimov
NPI 1114523719
$7,582.99
in general payments reported to CMS, 2019-2025
30 companies · $401 in 2025
The $401 reported for 2025 was more than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,017 · 2022: $3,215 · 2023: $1,678 · 2024: $272 · 2025: $401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,350.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,941.09 | 2021-2023 | Apretude, Cabenuva, Rukobia |
| Gilead Sciences, INC. | $1,420.03 | 2021-2023 | |
| Alexion Pharmaceuticals, INC. | $585.41 | 2021-2023 | |
| Novo Nordisk INC | $502.28 | 2021-2024 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $439.56 | 2021-2023 | |
| Janssen Biotech, INC. | $397.03 | 2021-2023 | Symtuza |
| Revance Therapeutics, INC. | $384.28 | 2025 | Daxxify |
| Janssen Products, LP | $300.73 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $287.73 | 2021-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $214.16 | 2021-2023 | Delstrigo, Pifeltro, Dificid |
| Lilly USA, LLC | $187.46 | 2021-2022 | |
| Galderma Laboratories, L.P. | $147.05 | 2024 | |
| Emd Serono, INC. | $124.80 | 2021-2023 | Serostim |
| Janssen Scientific Affairs, LLC | $111.98 | 2023 | Symtuza |
| Adaptive Biotechnologies Corporation | $103.01 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $71.56 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $48.61 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $48.41 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $43.52 | 2022 | |
| Boston Scientific Corporation | $35.28 | 2021 | |
| Napo Pharmaceuticals INC | $34.00 | 2021 | |
| Medtronic, INC. | $23.46 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $20.79 | 2022 | |
| Eisai INC. | $18.66 | 2022 | |
| Sanofi-Aventis U.S. LLC | $17.80 | 2022 | |
| Seqirus USA INC | $17.10 | 2021 | |
| Lucid Diagnostics INC. | $16.55 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $16.40 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $12.36 | 2022 | |
| Acerus Pharmaceuticals Corporation | $11.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniela Haimov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.